PAX3 and central nervous system neoplasm: Strikingly, we identified a large number of fusions (9/42; 21%), including novel fusions relevant for treatment (e.g., NFIA-RAF1 [12] and TFG-ROS1 [13] in CNS tumors) and fusions specifying disease origin (e.g., MN1-BEND2 for anaplastic ependymoma and PAX3-FOXO1 for rhabdomyosarcoma).